Back to Search
Start Over
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
- Source :
-
British journal of cancer [Br J Cancer] 2021 Aug; Vol. 125 (4), pp. 520-527. Date of Electronic Publication: 2021 May 26. - Publication Year :
- 2021
-
Abstract
- Background: Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We assessed the safety, tolerability, pharmacokinetics, and preliminary efficacy of berzosertib plus cisplatin.<br />Methods: Adult patients with advanced solid tumours refractory or resistant to standard of care therapies received ascending doses of cisplatin (day 1) and berzosertib (days 2 and 9) every 3 weeks (Q3W).<br />Results: Thirty-one patients received berzosertib (90-210 mg/m <superscript>2</superscript> ) and cisplatin (40-75 mg/m <superscript>2</superscript> ) across seven dose levels. The most common grade ≥3 treatment-emergent adverse events were neutropenia (20.0%) and anaemia (16.7%). There were two dose-limiting toxicities: a grade 3 hypersensitivity reaction and a grade 3 increase in alanine aminotransferase. Berzosertib 140 mg/m <superscript>2</superscript> (days 2 and 9) and cisplatin 75 mg/m <superscript>2</superscript> (day 1) Q3W was determined as the recommended Phase 2 dose. Cisplatin had no apparent effect on berzosertib pharmacokinetics. Of the 31 patients, four achieved a partial response (two confirmed and two unconfirmed) despite having previously experienced disease progression following platinum-based chemotherapy.<br />Conclusions: Berzosertib plus cisplatin is well tolerated and shows preliminary clinical activity in patients with advanced solid tumours, warranting further evaluation in a Phase 2 setting.<br />Clinical Trials Identifier: NCT02157792.<br /> (© 2021. The Author(s).)
- Subjects :
- Adult
Aged
Antineoplastic Combined Chemotherapy Protocols adverse effects
Cisplatin adverse effects
Cisplatin pharmacokinetics
Drug Administration Schedule
Drug Resistance, Neoplasm drug effects
Female
Humans
Isoxazoles adverse effects
Isoxazoles pharmacokinetics
Male
Middle Aged
Pyrazines adverse effects
Pyrazines pharmacokinetics
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Cisplatin administration & dosage
Isoxazoles administration & dosage
Neoplasms drug therapy
Pyrazines administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1532-1827
- Volume :
- 125
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- British journal of cancer
- Publication Type :
- Academic Journal
- Accession number :
- 34040174
- Full Text :
- https://doi.org/10.1038/s41416-021-01406-w